12:00 AM
 | 
Sep 17, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Tovanor Breezhaler: Additional Phase III data

Pooled data from 1,888 patients enrolled in the double-blind, international Phase III GLOW1 and GLOW2 trials showed that 50 µg once-daily NVA237 significantly increased trough FEV1 by 98 mL at day 1, 103 mL at 12 weeks, 125 mL at 26 weeks and 108 mL at 52 weeks vs. placebo (p<0.001 for all). NVA237 also significantly increased trough FVC by 187 mL at day 1, 190 mL at 12 weeks, 205 mL at 26 weeks and 179 mL at 52 weeks vs. placebo (p<0.001 for all). Additionally, NVA237 significantly increased FEV1 AUC from 0-4 hours, 0-12 hours, 0-24 hours and 12-24 hours vs. placebo on day 1 and weeks 12,...

Read the full 530 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >